MT-TP and metabolic dysfunction-associated steatohepatitis: MASH patients, in comparison with MASLD patients, exhibited lower expression of peroxisome proliferator-activated receptor α (PPAR-α), MTTP, and apoB100, but no changes were observed in SREBP1c, FASN, DGAT1 and 2, FABP and FATP, and CD36 [32,33,34].